Skip to main content

Advertisement

Table 2 Selected effectiveness parameters and steroid use

From: Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry

JADAS-10; median (IQR)a Month 0 Month 3 Month 6 Month 12 Month 18 Month 24 Last observation
 ETA 20.8 (14; 28.4) 6.9 (2.5; 14.3) 6.2 (1.1; 14.7) 3.8 (0.7; 15.7) 4.1 (1.5; 15.2) 3.3 (0.7; 9.4) 9.1 (2.1; 19.1)
 TOC 16.9 (8.1; 24.8) 3.6 (0.8; 10.7) 1.5 (0.2; 3.8) 1.6 (0.4; 6.7) 0.9 (0.2; 2.0) 0.9 (0.1; 7.5) 0.9 (0.1; 4)
 IL-1i 13 (6.7; 20.6) 0.8 (0.2; 1.6) 0.6 (0.2; 2.1) 0.8(0.2; 2.6) 0.2 (0; 1.9) 0.2 (0.1; 0.8) 0.8 (0.1; 5.1)
Patients with active systemic signs; n (%)b        
 ETA 2 (1%) 0 0 2 (2.5%) 0 0 1 (1%)
 TOC 30 (42%) 5 (14%) 3 (6%) 3 (7%) 2 (5%) 1 (4%) 4 (7%)
 IL-1i 40 (63%) 9 (32%) 8 (22%) 8 (21%) 8 (26%) 4 (17%) 6 (11%)
Active joints; median (IQR)a        
 ETA 4 (2; 11) 1 (0; 3) 1 (0; 5) 0 (0; 4) 0.5 (0; 4) 0.5 (0; 4) 1 (0; 6)
 TOC 3.0 (0; 6) 0 (0; 0.5) 0 (0; 0.3) 0 (0; 1.0) 0 (0; 0) 0 (0; 1.0) 0 (0; 0)
 IL-1i 2 (0; 5) 0 (0; 0.3) 0 (0; 0) 0 (0; 0) 0 (0; 0) 0 (0; 0) 0 (0; 0)
Patients with active joints; n (%)b        
 ETA 121 (85%) 48 (53%) 49 (52%) 39 (48%) 36 (50%) 36 (50%) 67 (53%)
 TOC 49 (69%) 9 (26%) 12 (25%) 13 (29%) 7 (19%) 8 (29%) 15 (21%)
 IL-1i 34 (60%) 7 (25%) 6 (17%) 8 (21%) 7 (23%) 2 (9%) 12 (21%)
Patients on steroid use; n (%)b        
 ETA 119 (83%) 66 (72%) 73 (76%) 48 (59%) 36 (49%) 35 (56%) 65 (49%)
 TOC 32 (44%) 13 (35%) 16 (31%) 7 (14%) 6 (15%) 8 (27%) 7 (11%)
 IL-1i 27 (45%) 12 (48%) 15 (45%) 10 (29%) 7 (25%) 6 (27%) 12 (24%)
  1. Data as observed
  2. JADAS Juvenile Disease Activity Score, ETA etanercept, TOC tocilizumab, IL-li interleukin-1 inhibitor
  3. aData are given as median and interquartile range of patients on treatment as observed. Note, the median value was higher in the last observation on ETA than on TOC or IL-1i
  4. bPercentage of patients reported